PLATO ACT 4 results for dose de-escalation in early-stage anal cancer are out! Prof Sebag-Montefiore presents on the plenary stage at #ESTRO24 3-year locoregional failure 16.4% for standard dose IMRT vs 12.4% reduced dose IMRT Reduced dose IMRT is safe & effective! #radonc

Thank you, Ane, for taking on one of the most requested topics from the young and early-career ESTRO members!

What about #SABR / #SBRT to the primary tumour in LA-NSCLC? This study just presented at #ESTRO25 has promising survival with little toxicity rates ➡️ improvement in PFS ➡️ trend toward better OS

Promising result! Why not consider (lower dose SIB) hypofractionated nodal RT as well with primary SBRT? #ESTRO2025 #lcsm Drew Moghanaki Percy Lee MD

Dose metrics linked to bowel toxicity for rectal RT in RAPIDO: Amazing work by Max Tanaka from NKI Medium-to-high dose volumes for bowel bag (RTOG or Embrace) best predictors for both acute & late toxicity - V30Gy for LCRT, V20Gy for short course #ESTRO25 #radonc #medphys

🚨 New Study on SBRT vs. Conventional RT for Painful Bone Metastases! 🚨OncoAlert 🎯 Study Objective Compare the effectiveness of dose-escalated SBRT (20 Gy) vs. conventional RT (8 Gy) in achieving complete pain response for painful bone metastases 🏥 Methods • Design: Phase

Thought provoking

Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/4jePW1F

‼️ TAUTEM Phase 3 RCT T2-3bN0M0 rectal cancer -> chemoradiation and transanal excision vs TME DFS in both groups was 88.9%! Win for organ preservation and patients! jamanetwork.com/journals/jamas…

Morning > Afternoon for IO? Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat). Given IO’s long half-life, maybe only the timing of the first dose matters. #ASCO2025

On that note, I wonder if radiation oncology will ever have a community like Radiopaedia one where we can share full stacks of images, volumes, DVHs, and meaningful discussions, all driven by the same communal spirit. It can feel quite lonely in radiation oncology at times.

While I'm here, I'll just point out that RCTs of SABR don't show that radiation leads to more metastases...if anything the relationship is going the other way. Here's the data from Dan Gomez's oligomets RCT...

❓ESTRO & EORTC proposed a classification to standardize reirradiation. But does it predict outcomes or toxicity? 🫁☢️ We applied the classification in thoracic reirradiation for NSCLC. Here’s what we found. 🧵

I feel fortunate to have become a lung cancer specialist in the early 2000s and to have witnessed these exciting advances in both technology and biology-based diagnosis and treatments.

What a story...

Say hello to “Strategic Radiotherapy”. QuadShot News theMednet

🧠 ESTRON Trial: Can We Skip WBRT After Brain Met Resection? 🎯 Objective Compare hypofractionated stereotactic RT (HFSRT, 35 Gy/7fx) vs. whole-brain RT (WBRT, 30 Gy/10fx) post brain metastasis surgery, assessing control, toxicity & cognition. 🏥 Methods Phase 2, randomized,

The latest data show nearly 70% of lung adenocarcinomas have a targetable mutation. #AABIP2025 #AABIP25 Eric K. Singhi, MD

Here's a patient recently randomized on our ARREST2 phase 2/3 RCT. Sixteen pulmonary mets, 35 Gy in 5 fractions. Constraints: V13.5 Gy <37%, 1500 cc of lung <12.5 Gy